Serum FAP⁺ exosome-based flow cytometric detection: potential utility in early diagnosis, disease progression assessment, and surgical response monitoring of lung adenocarcinoma.
A blood test using cancer-cell-derived particles detects early lung cancer with 88% accuracy, potentially catching the disease before symptoms appear.
A novel serum FAP+ exosome flow cytometric assay for lung adenocarcinoma achieved AUC 0.932 with 88.4% sensitivity and 87.6% specificity in a clinical cohort, significantly outperforming conventional biomarkers for early-stage LUAD and showing post-surgical response. This minimally invasive CAF-derived exosome biomarker may advance early detection beyond current standard serum markers.
What the study was
- Study design
- Prospective diagnostic accuracy study with clinical cohort (healthy donors, benign lesions, LUAD patients)
- Population
- Healthy donors (HD), patients with benign lung lesions (LBL), and lung adenocarcinoma (LUAD) patients
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Journal of Nanobiotechnology
Why it surfaced
Novel CAF-derived exosome biomarker with excellent early-stage LUAD diagnostic performance (AUC 0.932), superior to existing serum biomarkers. Clinical cohort validation is promising though sample sizes and clinical reproducibility need independent validation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.